Galecto Publishes GB0139 Phase 2a Idiopathic Pulmonary Fibrosis (IPF) Results in European Respiratory Journal, Showing Marked Impact on Several IPF Biomarkers
The ERJ Paper shows major effects on biomarkers in IPF, linked to mortality and to…
The ERJ Paper shows major effects on biomarkers in IPF, linked to mortality and to…
NEW HAVEN, Conn., Nov. 30, 2020 (GLOBE NEWSWIRE) — Kleo Pharmaceuticals, Inc., a targeted immunotherapy…
CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage…
Includes updated data from CPI-818 phase 1/1b trial and pre-clinical results supporting use in autoimmune…
BOSTON, Nov. 30, 2020 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused…
— Single-Ascending Doses of ALLN-346 Oral Enzyme Well-Tolerated —— Non-Absorption of ALLN-346 Demonstrated —— Advancing…
Review positive interim data from the study of itolizumab for the treatment of acute GVHD…
– Receptor occupancy and TDAR suppression shown through Day 29 at 3 mg/kg intravenous –…
SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology…
PHILADELPHIA, Nov. 30, 2020 (GLOBE NEWSWIRE) — Scout Bio, a biotechnology company revolutionizing pet medicine by…